Metastatic risk is determined by cytogenetic alterations; mainly monosomy of chromosome 3 (M3), amplification of chr8q, and inversely, by chr6p gain, by somatic mutations in BAP1 (high risk), SF3B1 (intermediate risk, metastasis with long latency), and EIF1AX (low risk), by cell shape (spindle or epithelioid cells), tumor thickness, basal diameter and by gene expression profile (class 1, class 2 signature) [11]. This evidence concerns the gene BAP1 and neoplasm.